NICE Technology Appraisal Explained
What is a NICE technology appraisal?
A NICE technology appraisal (TA) is a NICE evaluation of a single medicine, treatment or other technology, published as guidance numbered TAxxx, that recommends whether and how the NHS in England should use it. What makes TAs different from most NICE guidance is that the NHS has a legal duty to fund them. The 2013 NICE Regulations (Section 7) require integrated care boards, NHS England and, for their public health functions, local authorities "to comply with the recommendations" within a fixed period after publication. The NHS in Wales "must usually" fund recommended technologies under directions from Welsh ministers [1].
How it works in practice
- What is assessed. The appraisal committee weighs clinical effectiveness against cost effectiveness. It asks whether the most plausible ICER (incremental cost-effectiveness ratio) is within "the range NICE normally considers an acceptable use of NHS resources". When confidential discounts apply, the exact ICERs are not published [2].
- Types of outcome:
- Recommended as an option, sometimes across the whole marketing authorisation [3].
- Recommended "only if" certain conditions are met. These can be a specific patient subgroup or severity threshold, and that the company supplies the product under the agreed commercial arrangement [4].
- Not recommended.
- Terminated appraisal. NICE "is unable to make a recommendation", for example because the company did not provide an evidence submission. NICE reviews this if the company later submits [5].
- Funding deadlines. Recent guidance gives 90 days from publication. Older guidance says 3 months. Under the cost-comparison process, NHS England and integrated care boards have agreed to fund within 30 days [6]. In Wales the deadline is 60 days (2 months in older guidance) from first publication of the final draft guidance [7].
- Interim funding before routine funding:
- Some medicines can get early interim money from the Innovative Medicines Fund. It ends 90 days after positive final guidance, when funding switches to routine budgets [8].
- Cancer drugs can get the same from the Cancer Drugs Fund, starting at marketing authorisation or positive draft guidance, whichever is later [9].
- What "as an option" means for patients. The NHS "must make sure it is available" within the set period. If the clinician thinks the product is the right treatment, it should be available [10].
- Off-label use. The Department of Health has said the statutory funding requirement does not apply to drugs used outside their marketing authorisation [11].
Approach: I read published NICE technology appraisal guidance documents, mainly their recommendations and implementation sections. NICE's own pages (the technology appraisal overview and the PMG36 process manual) refused access, so I could not quote NICE's formal definition or its stated £-per-QALY thresholds.
How does the appraisal process work?
A NICE technology appraisal runs as a staged process. A topic is selected or prioritised, then scoped. The company submits evidence, which an independent academic group critiques. A standing NICE committee then makes a recommendation, consults on a draft, and issues final draft guidance. That can be appealed before publication, and the guidance can be reviewed later. I've traced each stage below from NICE's own project timelines and published guidance.
1. Topic selection and routing
- Topics are first "Selected" or "Prioritised". A recent example gave the reason as meeting the criteria of the 2024 Voluntary Scheme for Pricing, Access and Growth (VPAG) "as a new active substance" [12].
- NICE's Prioritisation Board decides the route. In one case it found that criteria 1, 3 and 4 of the highly specialised technology framework were not met, so the medicine went to the technology appraisals programme [13].
- The main routes shown are:
- "STA Standard" (single technology appraisal).
- "Cost Comparison Standard". For one medicine NICE switched mid-evaluation, citing "sections 4.2.13-21 and 5.8.23-27 of the manual" [14].
- NICE "cannot produce recommendations for treatments without a marketing authorisation". If the company stops pursuing an MHRA application, the appraisal is suspended [13].
2. Scoping
- NICE consults on a suggested remit, a draft scope and a provisional list of consultees and commentators. That consultation ran for four weeks in each example: 21 January to 18 February 2026, then a scoping workshop [15].
- Some topics are "stopped after scoping" and do not go on to an appraisal [16].
- The final scope sets the population and comparators. The evidence review group checks whether the company's submission departs from it [17].
3. Invitation to participate and stakeholders
- After an "Invitation to participate", the project lists its stakeholders [18]:
- the company
- the Department of Health and Social Care and NHS England
- patient groups and professional groups
- comparator companies
- general commentators, such as the MHRA, the Scottish Medicines Consortium and the Welsh Government
- Comparator companies may sign a confidentiality agreement to take part [14].
- Patient experts and clinical experts are chosen from nominations [19].
4. Evidence submission and independent critique
- The company submits evidence, and an External Assessment Group (EAG), formerly called the evidence review group (ERG), reviews it [20].
- The EAG can change the company's base-case modelling, and the committee decides which approach it prefers [21].
- If the company says it will not submit, NICE suspends the appraisal [22]. As covered last time, it can also end as a terminated appraisal.
- Older multi-technology appraisals worked differently. An academic group wrote the Assessment Report, and consultees could comment on the draft scope, the Assessment Report and the Appraisal Consultation Document [23].
5. Committee decision-making
- There are 4 standing technology appraisal committees. Members with a conflict of interest are excluded, and minutes are posted [24].
- The committee works from the cost per QALY (the ICER):
- Above a most plausible ICER of £20,000 per QALY gained, acceptability takes into account how certain the ICER is.
- The range NICE considers cost-effective is "£20,000 to £30,000 per QALY gained".
- Committees "may be able to accept a higher degree of uncertainty" for rare conditions [25].
- The committee "may apply a greater weight to QALYs (a severity modifier)" for severe conditions. Severity is measured by QALY shortfall, and one example applied a weight of 1.2 [21].
- Older appraisals instead used "end of life criteria" [26].
6. Draft guidance consultation
- The draft guidance is open for comment for about three weeks, for example 2 to 23 July 2025 [18].
- Commenters must comment on the online document and should read the committee papers first [27].
- One appraisal ran a second committee meeting, a second draft and a third committee meeting [18].
7. Final draft guidance and appeal
- Consultee organisations can appeal against the final document [23]. Older guidance calls it the "Final Appraisal Determination"; later guidance calls it the final draft guidance or "final appraisal document".
- An independent appeal panel holds an oral hearing. If it upholds a point, the appraisal goes back to committee. In TA883, a third committee meeting then considered the upheld point and a revised patient access scheme [28].
8. Publication, managed access and review
- Publication follows final draft guidance. In one cost-comparison case, final draft guidance was on 1 October 2026 and expected publication on 21 October 2026 [14].
- Where evidence is uncertain, NICE can recommend a treatment "for use with managed access". NHS England then makes it available under a managed access agreement, with interim funding from the Innovative Medicines Fund once positive final draft guidance is released [29].
- At the end of the data collection period, a "managed access review" is held [30]. Published guidance can also be reviewed separately [31].
Approach: I read NICE technology appraisal project timelines (in development and suspended) and published TA guidance documents. NICE's process and methods manual itself is not in the datasets, so the stage descriptions come from how the guidance and project pages apply it rather than from the manual's own text.
When must the NHS fund a recommended medicine?
In England, the NHS must fund a NICE-recommended medicine within 90 days of the technology appraisal guidance being published. Section 7 of the NICE (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 "requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 90 days of its date of publication" [1]. In Wales, the NHS "must usually" provide funding within 60 days of the first publication of the final draft guidance [32].
What the duty means
- When NICE recommends a treatment "as an option", the NHS "must make sure it is available" within that period. If the healthcare professional responsible for a patient thinks it is the right treatment, "it should be available for use, in line with NICE's recommendations" [1].
- The duty only covers use in line with the recommendations. The Department of Health has said "the statutory funding requirement does not apply to drugs that are used outside the terms of their marketing authorisation" [11].
Faster or different timelines in England
| Situation | Deadline |
|---|---|
| Standard (current guidance) | 90 days from publication [1] |
| Older guidance | "3 months" from publication, with clinical commissioning groups named instead of integrated care boards [33] |
| Recommended through the cost-comparison process | NHS England and integrated care boards "have agreed to provide funding to implement this guidance 30 days after publication" [32] |
| Medicine available through the Early Access to Medicines Scheme (EAMS) | Funding agreed 30 days after publication; the TA813 example is asciminib [33] |
| Guidance published before marketing authorisation | Clock runs from authorisation: "within 3 months of nivolumab and ipilimumab receiving its marketing authorisation" [34] |
Note that the 30-day cost-comparison and EAMS timelines are described as arrangements NHS England and the commissioners "have agreed" to. The 90-day period is the statutory one.
Interim funding before the statutory deadline
- Cancer Drugs Fund. For drugs with a draft recommendation for routine commissioning, interim funding is available "from the point of marketing authorisation, or from release of positive draft guidance, whichever is later". It ends 90 days after positive final guidance, or 30 days for drugs with an EAMS designation or a cost-comparison evaluation. Funding then switches to routine commissioning budgets [35].
- Innovative Medicines Fund. It is "a discretionary source of early funding" for certain NICE-recommended medicines. It ends on the same 90-day and 30-day schedule [1].
Managed access recommendations
- In England, NHS England "will make it available according to the conditions in the managed access agreement". Cancer Drugs Fund drugs are funded under that agreement from marketing authorisation or positive draft guidance, whichever is later [36].
- In Wales, the NHS "must usually" fund within 60 days of the first publication of the final draft guidance or the NHS in Wales agreeing a managed access agreement, "whichever is the later" [36].
Wales: older guidance Older guidance gave Wales "2 months" from the first publication of the final appraisal document [34].
Approach: I read the implementation sections of published NICE technology appraisal guidance, comparing older and current wording. The 2013 Regulations and the Welsh ministers' directions are not in the datasets I searched, so the duties are quoted as NICE states them in its guidance.